keyword
MENU ▼
Read by QxMD icon Read
search

Plasmodium vivax and treatment

keyword
https://www.readbyqxmd.com/read/27905633/-failure-to-radical-cure-in-plasmodium-vivax-malaria
#1
Julián García, Agustín Seijo, Andrés Benchetrit, Esteban Couto, Sofía Echazarreta, Susana Lloveras, Tomás Orduna
Relapsing Plasmodium vivax malaria is due to activation of dormant intrahepatic parasitic forms known as hypnozoits. Primaquine is the only available drug effective against hypnozoits and, alongside a schizonticidal drug, constitutes the radical treatment of malaria. Failure of radical treatment is frequently attributed to inadequate dosing, poor adherence, or reinfection. However, several cases of radical treatment failure without these factors have been reported, inferring that metabolic properties of the host or tolerance mechanisms of the parasite may be implied...
August 2016: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/27894320/successful-malaria-elimination-in-the-ecuador-peru-border-region-epidemiology-and-lessons-learned
#2
Lyndsay K Krisher, Jesse Krisher, Mariano Ambuludi, Ana Arichabala, Efrain Beltrán-Ayala, Patricia Navarrete, Tania Ordoñez, Mark E Polhemus, Fernando Quintana, Rosemary Rochford, Mercy Silva, Juan Bazo, Anna M Stewart-Ibarra
BACKGROUND: In recent years, malaria (Plasmodium vivax and Plasmodium falciparum) has been successfully controlled in the Ecuador-Peru coastal border region. The aim of this study was to document this control effort and to identify the best practices and lessons learned that are applicable to malaria control and to other vector-borne diseases. A proximal outcome evaluation was conducted of the robust elimination programme in El Oro Province, Ecuador, and the Tumbes Region, Peru. Data collection efforts included a series of workshops with local public health experts who played central roles in the elimination effort, review of epidemiological records from Ministries of Health, and a review of national policy documents...
November 28, 2016: Malaria Journal
https://www.readbyqxmd.com/read/27865203/minocycline-prevents-cerebral-malaria-confers-neuroprotection-and-increases-survivability-of-mice-during-plasmodium-berghei-anka-infection
#3
Thittayil Suresh Apoorv, Phanithi Prakash Babu
Cerebral malaria (CM) is a neurological complication arising due to Plasmodium falciparum or Plasmodium vivax infection. Minocycline, a semi-synthetic tetracycline, has been earlier reported to have a neuroprotective role in several neurodegenerative diseases. In this study, we investigated the effect of minocycline treatment on the survivability of mice during experimental cerebral malaria (ECM). The currently accepted mouse model, C57BL/6 mice infected with Plasmodium berghei ANKA, was used for the study...
November 16, 2016: Cytokine
https://www.readbyqxmd.com/read/27825387/plasmodium-vivax-multidrug-resistance-1-gene-polymorphism-in-french-guiana
#4
Emilie Faway, Lise Musset, Stéphane Pelleau, Béatrice Volney, Jessica Casteras, Valérie Caro, Didier Menard, Sébastien Briolant, Eric Legrand
BACKGROUND: Plasmodium vivax malaria is a major public health problem in French Guiana. Some cases of resistance to chloroquine, the first-line treatment used against P. vivax malaria, have been described in the Brazilian Amazon region. The aim of this study is to investigate a possible dispersion of chloroquine-resistant P. vivax isolates in French Guiana. The genotype, polymorphism and copy number variation, of the P. vivax multidrug resistance gene-1 (pvmdr1) have been previously associated with modification of the susceptibility to chloroquine...
November 8, 2016: Malaria Journal
https://www.readbyqxmd.com/read/27821127/treatment-seeking-behaviour-and-associated-costs-for-malaria-in-papua-indonesia
#5
Muhammad Karyana, Angela Devine, Enny Kenangalem, Lenny Burdarm, Jeanne Rini Poespoprodjo, Ram Vemuri, Nicholas M Anstey, Emiliana Tjitra, Ric N Price, Shunmay Yeung
BACKGROUND: Malaria remains a significant public health issue in Eastern Indonesia, where multidrug resistant Plasmodium falciparum and Plasmodium vivax are highly prevalent. The objective of this study was to describe treatment-seeking behaviour and household costs prior to a change to a unified treatment policy of dihydroartemisinin-piperaquine in Mimika district, Papua province in 2006. METHODS: In 2005 a randomized cross-sectional household survey was conducted to collect data on demographics, socio-economic status (SES), treatment-seeking, case management, and household costs...
November 8, 2016: Malaria Journal
https://www.readbyqxmd.com/read/27799636/implications-of-plasmodium-vivax-biology-for-control-elimination-and-research
#6
Piero L Olliaro, John W Barnwell, Alyssa Barry, Kamini Mendis, Ivo Mueller, John C Reeder, G Dennis Shanks, Georges Snounou, Chansuda Wongsrichanalai
This paper summarizes our current understanding of the biology of Plasmodium vivax, how it differs from Plasmodium falciparum, and how these differences explain the need for P. vivax-tailored interventions. The article further pinpoints knowledge gaps where investments in research are needed to help identify and develop such specific interventions. The principal obstacles to reduce and eventually eliminate P. vivax reside in 1) its higher vectorial capacity compared with P. falciparum due to its ability to develop at lower temperature and over a shorter sporogonic cycle in the vector, allowing transmission in temperate zones and making it less sensitive to vector control measures that are otherwise effective on P...
October 31, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27785088/acute-kidney-injury-in-a-shepherd-with-severe-malaria-a-case-report
#7
Boushab Mohamed Boushab, Fatim-Zahra Fall-Malick, Mamoudou Savadogo, Leonardo Kishi Basco
Malaria is one of the main reasons for outpatient consultation and hospitalization in Mauritania. Although four Plasmodium species, ie, Plasmodium (P.) falciparum, P. vivax, P. malariae, and P. ovale, cause malaria in Mauritania, recent data on their frequency is lacking. Since infections with P. falciparum generally result in serious disease, their identification is important. We report a case of oliguric renal injury associated with malaria in a 65-year-old shepherd. Clinical manifestations included anemia, oliguria, and elevated creatinine and urea...
2016: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/27767381/the-effect-of-snps-in-cyp450-in-chloroquine-primaquine-plasmodium-vivax-malaria-treatment
#8
Vinicius A Sortica, Juliana D Lindenau, Maristela G Cunha, Maria DO Ohnishi, Ana Maria R Ventura, Ândrea Kc Ribeiro-Dos-Santos, Sidney Eb Santos, Luciano Sp Guimarães, Mara H Hutz
BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS & METHODS: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients...
October 21, 2016: Pharmacogenomics
https://www.readbyqxmd.com/read/27759110/plasmodium-vivax-gpi-anchored-micronemal-antigen-pvgama-binds-human-erythrocytes-independent-of-duffy-antigen-status
#9
Yang Cheng, Feng Lu, Bo Wang, Jian Li, Jin-Hee Han, Daisuke Ito, Deok-Hoon Kong, Lubin Jiang, Jian Wu, Kwon-Soo Ha, Eizo Takashima, Jetsumon Sattabongkot, Jun Cao, Myat Htut Nyunt, Myat Phone Kyaw, Sanjay A Desai, Louis H Miller, Takafumi Tsuboi, Eun-Taek Han
Plasmodium vivax, a major agent of malaria in both temperate and tropical climates, has been thought to be unable to infect humans lacking the Duffy (Fy) blood group antigen because this receptor is critical for erythrocyte invasion. Recent surveys in various endemic regions, however, have reported P. vivax infections in Duffy-negative individuals, suggesting that the parasite may utilize alternative receptor-ligand pairs to complete the erythrocyte invasion. Here, we identified and characterized a novel parasite ligand, Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA), that bound human erythrocytes regardless of Duffy antigen status...
October 19, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27751864/evaluation-of-the-lh780-hematology-analyzer-for-detection-and-therapeutic-monitoring-of-malaria-cross-reactivity-with-nucleated-rbcs
#10
Jung Yoon, Seung Gyu Yun, Jeeyong Kim, Yoo Na Jung, Young Eun Koh, Jeong Hun Nam, Eun Taek Han, Chae Seung Lim
We evaluated the diagnostic usefulness of the LH780 Coulter blood cell counter for detection and therapeutic monitoring of malaria including cross-reactivity with nucleated RBC (NRBC) samples. A total of 405 patients (43 patients with Plasmodium vivax malaria and the control group of 120 healthy subjects, 111 patients with fever, and 131 patients with NRBCs) were analyzed with routine CBC using the LH780. We analyzed the CBC results according to three selected parameters: an abnormal peak in the WBC histogram before 35fL, the presence of red dots in the nonwhite cell zone of 2D WBC Diff Dataplot, and platelet-related flags suggesting platelet clumps or giant platelets...
October 14, 2016: Acta Tropica
https://www.readbyqxmd.com/read/27708191/diagnosis-and-treatment-of-plasmodium-vivax-malaria
#11
J Kevin Baird, Neena Valecha, Stephan Duparc, Nicholas J White, Ric N Price
The diagnosis and treatment of Plasmodium vivax malaria differs from that of Plasmodium falciparum malaria in fundamentally important ways. This article reviews the guiding principles, practices, and evidence underpinning the diagnosis and treatment of P vivax malaria.
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27708189/epidemiology-and-control-of-plasmodium-vivax-in-afghanistan
#12
Toby Leslie, Sami Nahzat, Walid Sediqi
Around half of the population of Afghanistan resides in areas at risk of malaria transmission. Two species of malaria (Plasmodium vivax and Plasmodium falciparum) account for a high burden of disease-in 2011, there were more than 300,000 confirmed cases. Around 80-95% of malaria is P. vivax Transmission is seasonal and focal, below 2,000 m in altitude, and in irrigated areas which allow breeding of anopheline mosquito vectors. Malaria risk is stratified to improve targeting of interventions. Sixty-three of 400 districts account for ∼85% of cases, and are the target of more intense control efforts...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27697758/pharmacokinetic-interactions-between-tafenoquine-and-dihydroartemisinin-piperaquine-or-artemether-lumefantrine-in-healthy-adult-subjects
#13
Justin A Green, Khadeeja Mohamed, Navin Goyal, Samia Bouhired, Azra Hussaini, Siôn W Jones, Gavin C K W Koh, Ivan Kostov, Maxine Taylor, Allen Wolstenholm, Stephan Duparc
Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin-based combination therapy (ACT). This open-label, randomized, parallel-group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin-piperaquine and artemether-lumefantrine. Healthy volunteers of either sex aged 18 to 65 years without glucose-6-phosphate dehydrogenase deficiency were randomized into five cohorts (n = 24 per cohort) to receive tafenoquine on day 1 (300 mg) plus once-daily dihydroartemisinin-piperaquine on days 1, 2, and 3 (120 mg/960 mg for 36 to <75 kg of body weight and 160 mg/1,280 mg for ≥75 to 100 kg of body weight), or plus artemether-lumefantrine (80 mg/480 mg) in two doses 8 h apart on day 1 and then twice daily on days 2 and 3, or each drug alone...
December 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27663527/plasmodium-vivax-msp-3%C3%AE-polymorphisms-analysis-in-the-indian-subcontinent
#14
Anju Verma, Hema Joshi, Vineeta Singh, Anup Anvikar, Neena Valecha
BACKGROUND: Plasmodium vivax is the most widely distributed human malaria parasite and accounts for approximately the same number of malaria cases as Plasmodium falciparum in India. Compared with P. falciparum, P. vivax is difficult to eradicate because of its tendency to cause relapses, which impacts treatment and control strategies. The genetic diversity of these parasites, particularly of the merozoite surface protein-3 alpha (msp-3α) gene, can be used to help develop a potential vaccine...
2016: Malaria Journal
https://www.readbyqxmd.com/read/27658591/characteristics-of-imported-malaria-and-species-of-plasmodium-involved-in-shandong-province-china-2012-2014
#15
Chao Xu, Qing-Kuan Wei, Jin Li, Ting Xiao, Kun Yin, Chang-Lei Zhao, Yong-Bin Wang, Xiang-Li Kong, Gui-Hua Zhao, Hui Sun, Xin Liu, Bing-Cheng Huang
Malaria remains a serious public health problem in Shandong Province, China; therefore, it is important to explore the characteristics of the current malaria prevalence situation in the province. In this study, data of malaria cases reported in Shandong during 2012-2014 were analyzed, and Plasmodium species were confirmed by smear microscopy and nested-PCR. A total of 374 malaria cases were reported, 80.8% of which were reported from 6 prefectures. Of all cases, P. falciparum was dominant (81.3%), followed by P...
August 2016: Korean Journal of Parasitology
https://www.readbyqxmd.com/read/27651968/congenital-malaria-due-to-plasmodium-vivax-infection-in-a-neonate
#16
Ravi Bhatia, Dinesh Rajwaniya, Priti Agrawal
Although malaria is endemic in India, congenital malaria is not very common. Congenital malaria is a very rare condition in both endemic and nonendemic areas. We report a case of congenital malaria in a six-day-old neonate with fever and splenomegaly. The diagnosis was picked up accidentally on a peripheral smear examination. Congenital malaria should be kept as differential diagnosis of neonatal sepsis. Timely detection of this condition could lead to early diagnosis and treatment, thereby preventing neonatal mortality...
2016: Case Reports in Pediatrics
https://www.readbyqxmd.com/read/27641613/a-triazolopyrimidine-based-dihydroorotate-dehydrogenase-inhibitor-with-improved-drug-like-properties-for-treatment-and-prevention-of-malaria
#17
Margaret A Phillips, Karen L White, Sreekanth Kokkonda, Xiaoyi Deng, John White, Farah El Mazouni, Kennan Marsh, Diana R Tomchick, Krishne Manjalanagara, Kakali Rani Rudra, Grennady Wirjanata, Rintis Noviyanti, Ric N Price, Jutta Marfurt, David M Shackleford, Francis C K Chiu, Michael Campbell, Maria Belen Jimenez-Diaz, Santiago Ferrer Bazaga, Iñigo Angulo-Barturen, Maria Santos Martinez, Maria Lafuente-Monasterio, Werner Kaminsky, Kigbafori Silue, Anne-Marie Zeeman, Clemens Kocken, Didier Leroy, Benjamin Blasco, Emilie Rossignol, Thomas Rueckle, Dave Matthews, Jeremy N Burrows, David Waterson, Michael J Palmer, Pradipsinh K Rathod, Susan A Charman
The emergence of drug-resistant malaria parasites continues to hamper efforts to control this lethal disease. Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria, and a selective inhibitor (DSM265) of the Plasmodium enzyme is currently in clinical development. With the goal of identifying a backup compound to DSM265, we explored replacement of the SF5-aniline moiety of DSM265 with a series of CF3-pyridinyls while maintaining the core triazolopyrimidine scaffold...
October 4, 2016: ACS Infectious Diseases
https://www.readbyqxmd.com/read/27639847/safety-efficacy-and-pharmacokinetic-evaluations-of-a-new-coated-chloroquine-tablet-in-a-single-arm-open-label-non-comparative-trial-in-brazil-a-step-towards-a-user-friendly-malaria-vivax-treatment
#18
Dhelio Pereira, André Daher, Graziela Zanini, Ivan Maia, Lais Fonseca, Luciana Pitta, Rosilene Ruffato, Paola Marchesini, Cor Jesus Fontes
BACKGROUND: Malaria remains a major public health problem, with half the world population at risk of contracting malaria. The effects of Plasmodium vivax on prosperity and longevity have been highlighted in several recent clinical case reports. The first line of vivax treatment drugs has seen no radical innovation for more than 60 years. This study introduces a subtle incremental innovation to vivax treatment: a chloroquine and primaquine co-blister. The co-blister includes a new chloroquine formulation incorporating coated tablets to mask the drug's bitter taste and user-friendly packaging containing tablets of each drug, which may improve patient adherence and facilitate the appropriate use of the drugs...
2016: Malaria Journal
https://www.readbyqxmd.com/read/27630842/simple-molecular-methods-for-early-detection-of-chloroquine-drug-resistance-in-plasmodium-vivax-and-plasmodium-falciparum
#19
Gurjeet Singh, Raksha Singh, Anant Dattatraya Urhehar
INTRODUCTION: Malaria is a human disease of which causes high morbidity and mortality. In Plasmodium falciparum malaria, the resistance to antimalarial drugs, especially chloroquine (CQ) is one of the paramount factors contributing to the global increase in morbidity and mortality, due to malaria. Hence, there is a need for detection of chloroquine drug resistance genes i.e., pfcrt-o (Plasmodium falciparum chloroquine resistance transporter-o) and pfmdr-1 (Plasmodium falciparum multidrug resistance-1) of P...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27630198/nitric-oxide-dependent-endothelial-dysfunction-and-reduced-arginine-bioavailability-in-vivax-malaria-but-no-greater-increase-in-intravascular-haemolysis-in-severe-disease
#20
Bridget E Barber, Timothy William, Matthew J Grigg, Kim A Piera, Youwei Chen, Hao Wang, J Brice Weinberg, Tsin W Yeo, Nicholas M Anstey
BACKGROUND:  Pathogenesis of severe Plasmodium vivax malaria is poorly understood. Endothelial dysfunction and reduced nitric-oxide (NO) bioavailability characterise severe falciparum malaria, but have not been assessed in severe vivax malaria. METHODS:  In patients with severe (n=9) and non-severe (n=58) vivax malaria, and in healthy controls (HCs, N=79) we measured NO-dependent endothelial function using reactive hyperemia-peripheral arterial tonometry (RH-PAT), and assessed associations with arginine, asymmetric dimethylarginine (ADMA) and haemolysis...
September 13, 2016: Journal of Infectious Diseases
keyword
keyword
11896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"